Circulating Tumor Cells Market to Grow with a CAGR of 7.52% through 2030
Surge in research and development activities is
expected to drive the Global Circulating Tumor Cells Market growth in the
forecast period, 2026-2030.
According to TechSci Research report, “Circulating
Tumor Cells Market - Global Industry Size, Share, Trends, Competition
Forecast & Opportunities, 2030F”, the Global Circulating Tumor Cells
Market stood at USD 6.96 Billion in 2024 and is anticipated to grow with a CAGR
of 7.52% through 2030. Initiatives taken by government based on circulating
tumor cells has led to favorable market conditions for the Global Circulating
Tumor Cells Market. Several factors contribute to the growth of various circulating
tumor cells products.
One of the critical areas of R&D investment is the
development of more sensitive, efficient, and accurate CTC detection and
isolation technologies. Given that CTCs exist in extremely low concentrations
in the bloodstream, researchers are constantly innovating to improve methods of
capturing and analyzing these rare cells. Innovations in microfluidic devices,
immunomagnetic separation techniques, and next-generation sequencing have
significantly enhanced the ability to detect CTCs with greater precision,
driving the market forward. These advancements are enabling more effective
real-time monitoring of tumor progression and treatment responses, reinforcing
the clinical value of CTCs in oncology.
Governments are investing heavily in research and development for advanced cancer diagnostics, including CTC-based technologies. In countries like the United States, research agencies such as the National Cancer Institute (NCI) have provided substantial grants to support projects focused on isolating and analyzing CTCs. Similarly, the European Union’s Horizon Europe program has dedicated funds to cancer diagnostics research, with a focus on innovative non-invasive techniques like liquid biopsies that rely on CTC detection.
Browse over XX market data Figures spread
through XX Pages and an in-depth TOC on "Global Circulating Tumor Cells Market”
The Global Circulating Tumor Cells Market is segmented
into product, technology, regional distribution, and company.
Based on Product, Blood Collection Tubes
have emerged as the dominating segment in the Global Circulating Tumor Cells
Market in 2024. One of the primary reasons for the
prominence of blood collection tubes in the CTC market is their vital function
in maintaining the viability and integrity of circulating tumor cells. Since
CTCs are rare and fragile, it is crucial that they are preserved effectively
from the moment of collection to the time of analysis. Blood collection tubes,
specially designed for CTC isolation, contain stabilizing agents that prevent
cell degradation and coagulation, ensuring that CTCs remain intact during
transport and storage. This reliability has made blood collection tubes an
essential tool in clinical and research settings, leading to their widespread
adoption and dominance in the market.
Based on Region, Asia Pacific have emerged as the fastest
growing region in the Global Circulating Tumor Cells Market in 2024. The region
has witnessed a significant increase in cancer cases due to lifestyle changes,
aging populations, and environmental factors. This growing burden of cancer has
created a high demand for advanced diagnostic tools like CTC detection, driving
market growth across Asia Pacific.
Major companies operating in Global Circulating Tumor
Cells Market are:
- QIAGEN N.V.
- Bio-Techne Corp.
- Precision Medicine Group, LLC
- Bio-Rad Laboratories, Inc.
- Natera, Inc.
- Illumina, Inc.
- Greiner Bio-One International GmbH
- Ikonisys Inc.
- Creative Bioarray
- Abnova Corporation
Download Free Sample Report
Customers can also request for 10%
free customization on this report
“Nanotechnology-based platforms are revolutionizing
the ability to detect and isolate circulating tumor cells from the bloodstream.
Nanomaterials, such as nanoparticles and nanowires, are used to create highly
sensitive detection systems that can capture even the smallest number of CTCs.
These nanostructures are functionalized with specific antibodies or ligands
that bind to the surface markers on CTCs, enabling precise and selective
isolation. This increased sensitivity is essential for identifying CTCs in the
early stages of cancer, significantly improving early diagnosis and treatment outcomes”,
said Mr. Karan Chechi, Research Director of TechSci Research, a research-based
management consulting firm.
“Circulating Tumor Cells Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Product (Kits & Reagents, Blood Collection Tubes, Devices or Systems), By Technology (CTC Detection & Enrichment Methods, CTC Direct Detection Methods, CTC Analysis), By Region and Competition, 2020-2030F”, has evaluated
the future growth potential of Global Circulating Tumor Cells Market and
provides statistics & information on market size, structure, and future
market growth. The report intends to provide cutting-edge market intelligence
and help decision makers take sound investment decisions. Besides, the report
also identifies and analyzes the emerging trends along with essential drivers,
challenges, and opportunities in Global Circulating Tumor Cells Market.
Contact
TechSci Research LLC
420 Lexington Avenue, Suite 300,
New York, United States- 10170
Tel: +1-332-258-6602
Email: sales@techsciresearch.com
Website: www.techsciresearch.com